Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02447302




Registration number
NCT02447302
Ethics application status
Date submitted
13/05/2015
Date registered
18/05/2015
Date last updated
5/04/2021

Titles & IDs
Public title
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
Scientific title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients With Moderately to Severely Active Ulcerative Colitis
Secondary ID [1] 0 0
2015-001942-28
Secondary ID [2] 0 0
APD334-003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Etrasimod
Treatment: Drugs - Placebo

Experimental: Etrasimod Low Dose - Oral, low dose, daily for 12 Weeks

Experimental: Etrasimod High Dose - Oral, high dose, daily for 12 weeks

Placebo Comparator: Placebo - Oral, placebo, daily for 12 weeks.


Treatment: Drugs: Etrasimod


Treatment: Drugs: Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Adapted Mayo Score (MCS) at Week 12
Timepoint [1] 0 0
Baseline and Week 12
Secondary outcome [1] 0 0
Percentage of Participants Who Achieved Endoscopic Improvement at Week 12
Timepoint [1] 0 0
Week 12
Secondary outcome [2] 0 0
Change From Baseline in 2-component MCS at Week 12
Timepoint [2] 0 0
Baseline and Week 12
Secondary outcome [3] 0 0
Change From Baseline in Total Mayo Score (TMS) at Week 12
Timepoint [3] 0 0
Baseline and Week 12

Eligibility
Key inclusion criteria
- Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic
score

- Evidence of colonic ulcerative colitis activity on endoscopy
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Within 30 days prior to randomization, receipt of any of the following for the
treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus,
tofacitinib, thalidomide), a non-biologic investigational therapy or an approved
non-biologic therapy in an investigational protocol

- Within 60 days prior to randomization, receipt of any of the following: Infliximab,
adalimumab, golimumab, certolizumab, vedolizumab, any other investigational or
approved biologic agent

- Any prior exposure to natalizumab, efalizumab, or rituximab

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/10/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/02/2018
Sample size
Target
Accrual to date
Final
156
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Arena 1604 - Kingswood
Recruitment hospital [2] 0 0
Arena 1605 - Randwick
Recruitment hospital [3] 0 0
Arena 1607 - Subiaco
Recruitment postcode(s) [1] 0 0
2747 - Kingswood
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Utah
Country [13] 0 0
United States of America
State/province [13] 0 0
Virginia
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
United States of America
State/province [15] 0 0
Wisconsin
Country [16] 0 0
Austria
State/province [16] 0 0
Wien
Country [17] 0 0
Belgium
State/province [17] 0 0
Edegem
Country [18] 0 0
Belgium
State/province [18] 0 0
Kortrijk
Country [19] 0 0
Belgium
State/province [19] 0 0
Löwen
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Ruse
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sofia
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Varna
Country [23] 0 0
Canada
State/province [23] 0 0
Manitoba
Country [24] 0 0
Canada
State/province [24] 0 0
Nova Scotia
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Czechia
State/province [26] 0 0
Praha 4
Country [27] 0 0
France
State/province [27] 0 0
Amiens Cedex 1
Country [28] 0 0
France
State/province [28] 0 0
Clichy
Country [29] 0 0
France
State/province [29] 0 0
Lille Cedex 1443
Country [30] 0 0
France
State/province [30] 0 0
Paris
Country [31] 0 0
France
State/province [31] 0 0
Pierre-Benite
Country [32] 0 0
France
State/province [32] 0 0
Saint-Etienne Cedex 1
Country [33] 0 0
France
State/province [33] 0 0
Vandoeuvre-les-Nancy
Country [34] 0 0
Germany
State/province [34] 0 0
Hamburg
Country [35] 0 0
Germany
State/province [35] 0 0
Hanover
Country [36] 0 0
Germany
State/province [36] 0 0
Kiel
Country [37] 0 0
Germany
State/province [37] 0 0
Leipzig
Country [38] 0 0
Germany
State/province [38] 0 0
Oldenburg
Country [39] 0 0
Germany
State/province [39] 0 0
Ulm
Country [40] 0 0
Hungary
State/province [40] 0 0
Bekescsaba
Country [41] 0 0
Hungary
State/province [41] 0 0
Budapest
Country [42] 0 0
Hungary
State/province [42] 0 0
Debrecen
Country [43] 0 0
Hungary
State/province [43] 0 0
Szombathely
Country [44] 0 0
Israel
State/province [44] 0 0
Beer Sheva
Country [45] 0 0
Israel
State/province [45] 0 0
Haifa
Country [46] 0 0
Israel
State/province [46] 0 0
Holon
Country [47] 0 0
Israel
State/province [47] 0 0
Jerusalem
Country [48] 0 0
Israel
State/province [48] 0 0
Petah-Tikva
Country [49] 0 0
Korea, Republic of
State/province [49] 0 0
Busan
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Daegu
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Incheon
Country [52] 0 0
Korea, Republic of
State/province [52] 0 0
Seoul
Country [53] 0 0
Korea, Republic of
State/province [53] 0 0
Suwon-si
Country [54] 0 0
Korea, Republic of
State/province [54] 0 0
Wonju
Country [55] 0 0
Latvia
State/province [55] 0 0
Riga
Country [56] 0 0
Lithuania
State/province [56] 0 0
Vilnius
Country [57] 0 0
New Zealand
State/province [57] 0 0
Christchurch
Country [58] 0 0
Poland
State/province [58] 0 0
Bydgoszcz
Country [59] 0 0
Poland
State/province [59] 0 0
Elblag
Country [60] 0 0
Poland
State/province [60] 0 0
Kielce
Country [61] 0 0
Poland
State/province [61] 0 0
Krakow
Country [62] 0 0
Poland
State/province [62] 0 0
Lodz
Country [63] 0 0
Poland
State/province [63] 0 0
Posen
Country [64] 0 0
Poland
State/province [64] 0 0
Rzeszow
Country [65] 0 0
Poland
State/province [65] 0 0
Sopot
Country [66] 0 0
Poland
State/province [66] 0 0
Wroclaw
Country [67] 0 0
Romania
State/province [67] 0 0
Bucharest
Country [68] 0 0
Romania
State/province [68] 0 0
Iasi
Country [69] 0 0
Romania
State/province [69] 0 0
Oradea
Country [70] 0 0
Romania
State/province [70] 0 0
Timisoara
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Kazan'
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Krasnoyarsk
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Novosibirsk
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Rostov on Don
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Ryazan'
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Saint Petersburg
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Samara
Country [78] 0 0
Spain
State/province [78] 0 0
Barcelona
Country [79] 0 0
Spain
State/province [79] 0 0
Madrid
Country [80] 0 0
Spain
State/province [80] 0 0
Pontevedra
Country [81] 0 0
Spain
State/province [81] 0 0
Santiago de Compostela
Country [82] 0 0
Spain
State/province [82] 0 0
Sevilla
Country [83] 0 0
Ukraine
State/province [83] 0 0
Chernivtsi
Country [84] 0 0
Ukraine
State/province [84] 0 0
Ivano-Frankivsk
Country [85] 0 0
Ukraine
State/province [85] 0 0
Kharkov
Country [86] 0 0
Ukraine
State/province [86] 0 0
Kiev
Country [87] 0 0
Ukraine
State/province [87] 0 0
Kyiv
Country [88] 0 0
Ukraine
State/province [88] 0 0
Odessa
Country [89] 0 0
Ukraine
State/province [89] 0 0
Uzhgorod
Country [90] 0 0
Ukraine
State/province [90] 0 0
Vinnytsia
Country [91] 0 0
Ukraine
State/province [91] 0 0
Vinnytsya
Country [92] 0 0
United Kingdom
State/province [92] 0 0
London
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Torquay
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Arena Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment
for ulcerative colitis.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02447302
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Arena CT.gov Administrator
Address 0 0
Arena Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02447302